Evidence map›Paper›PMID 42629943›Full record

ArticleJournal of separation science2026

Establishing a Robust High Performance Liquid Chromatography-Ultraviolet Detection Technique for Nitrite Quantification in Pharmaceutical Excipients and Active Pharmaceutical Ingredients.

Kelly Blundin, Syamantak Roy, Edward Mularz, Junyong Jo

Abstract readEvaluation Study
In one paragraph

Article in Journal of separation science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kelly BlundinSmall Molecule Analytical Research and Development, Merck & Co. Inc., Rahway, New Jersey, USA.ORCID https://orcid.org/0009-0000-6185-3187
Syamantak RoySmall Molecule Analytical Research and Development, Merck & Co. Inc., Rahway, New Jersey, USA.ORCID https://orcid.org/0000-0002-6244-9896
Edward MularzSmall Molecule Analytical Research and Development, Merck & Co. Inc., Rahway, New Jersey, USA.
Junyong JoSmall Molecule Analytical Research and Development, Merck & Co. Inc., Rahway, New Jersey, USA.ORCID https://orcid.org/0000-0002-5134-3754

Funding

Merck & Co., Inc., Rahway, NJ, USA Future Talent ProgramResearch Laboratories of Merck & Co., Inc., Rahway, NJ, USA
6 · The paper itself

Abstract

Nitrite impurities are frequently present in pharmaceutical excipients as a result of raw material sources and manufacturing processes. These impurities are of regulatory concern because nitrite can react with secondary amines to form nitrosamines, a class of potentially mutagenic compounds, making effective control of nitrite critical to ensuring the safety of pharmaceutical products. Current industrial methods for nitrite detection and quantification, such as ion chromatography and related techniques, are often limited by aqueous solvent compatibility, matrix dependence, or restricted instrument availability, which can hinder routine implementation across diverse pharmaceutical materials. In this study, a fast and sensitive analytical approach was developed to address these limitations by enabling nitrite quantification across excipients spanning a broad range of hydrophilicity to hydrophobicity. The method employs a newly developed nitrite isolation strategy from solid pharmaceutical excipient matrices, followed by rapid derivatization to form a UV-active species that can be selectively quantified using high-performance liquid chromatography with ultraviolet detection (HPLC-UV). The resulting workflow demonstrates robust performance for low-level nitrite detection while maintaining compatibility with standard HPLC instrumentation across the diverse ranges of tested pharmaceutical ingredients. The widespread availability of HPLC systems, combined with the method's rapid response, selectivity, and low detection limits for nitrite, supports its adoption for routine analytical control. This approach, therefore, provides a practical tool for nitrite monitoring and mitigation of nitrosamine formation risk in pharmaceutical formulations.

Indexed as

ExcipientsNitritesBulk DrugsChromatography, High Pressure LiquidDrug ContaminationSpectrophotometry, UltravioletBulk DrugsExcipientsNitritesHPLC‐UVmethod developmentnitrite quantificationnitrosamines

Identifiers

PMID42629943
PMCPMC13498764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.